US Patent

US8377453 — Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic

Method of Use · Assigned to Depomed Inc · Expires 2029-11-19 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a dosage form that releases acetaminophen and an opioid in the upper gastrointestinal tract of a mammal for an extended period of time.

USPTO Abstract

Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (âGIâ) of a mammal for an extended period of time.

Drugs covered by this patent

chembl-chembl112 (ACETAMINOPHEN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1499`	—	chembl-chembl112

Patent Metadata

Patent number: US8377453
Jurisdiction: US
Classification: Method of Use
Expires: 2029-11-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Depomed Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.